- Home
- RBNE vs BLRX Comparison
RBNE vs BLRX Comparison
Compare RBNE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBNE | BLRX |
|---|---|---|
| Founded | 2024 | 2003 |
| Country | Cyprus | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 17.1M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | RBNE | BLRX |
|---|---|---|
| Price | $0.77 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 219.0K | 28.9K |
| Earning Date | 10-23-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.67 | $2.30 |
| 52 Week High | $24.65 | $14.70 |
Technical Indicators
Market Signals| Indicator | RBNE | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 42.87 |
| Support Level | $0.85 | $3.14 |
| Resistance Level | $0.89 | $3.43 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 23.69 | 10.40 |
Price Performance
Historical ComparisonAbout RBNE Robin Energy Ltd.
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.